I85PREP
⌘ K
ACRP-CP study materials
ACRP-CP study resources

ACRP-CP practice questions

One question at a time. Build your ACRP-CP understanding.

First 50 of 199 questions. Each one lists the choices, the correct answer, and an explanation. The checker at the top of this page saves progress in this browser when it is available.

Continue in the practice tool above to load more questions, 50 at a time.

Question 1Scientific Concepts and Research Design

Which is the primary objective of a Phase I clinical trial of an investigational drug?

  1. To monitor long-term rare adverse events after marketing approval
  2. To confirm efficacy compared with placebo in a large population
  3. To establish comparative effectiveness against standard therapy
  4. To characterize safety, tolerability, and pharmacokinetics Correct answer.

Explanation

Phase I studies typically enroll small numbers of participants and focus on dose, safety, tolerability, and pharmacokinetic behavior. They are not powered or designed to demonstrate efficacy, which is evaluated in later phases.

Question 2Scientific Concepts and Research Design

What is the main scientific purpose of including a placebo control arm in a randomized trial?

  1. To increase statistical power by enlarging the total sample size
  2. To separate the treatment effect from placebo response and natural variation Correct answer.
  3. To eliminate the need for random allocation of participants
  4. To guarantee that every participant receives an active treatment

Explanation

A placebo arm accounts for placebo response, regression to the mean, and the natural fluctuation of disease. The difference between the active and placebo arms isolates the treatment-specific effect.

Question 3Scientific Concepts and Research Design

Random allocation of participants to treatment groups primarily serves to:

  1. Guarantee that the groups have identical baseline characteristics
  2. Prevent participants from knowing which treatment they receive
  3. Ensure that each group receives an equal number of participants
  4. Reduce systematic differences by distributing known and unknown confounders Correct answer.

Explanation

Randomization gives each participant a known probability of assignment, so confounders tend to be distributed similarly across arms. The balance is probabilistic, not guaranteed, and allocation concealment rather than randomization itself prevents foreknowledge of assignment.

Question 4Scientific Concepts and Research Design

In a double-blind clinical trial, which parties are kept unaware of treatment assignment?

  1. The monitor and the sponsor's study manager are unaware of the assigned treatment
  2. Both participants and the investigator team are unaware Correct answer.
  3. Only the participants are unaware of their assigned treatment
  4. Only the outcome assessors are unaware of the assigned treatment

Explanation

Double-blind describes a trial in which participants and investigator-side personnel who administer or evaluate treatment, including outcome assessors, do not know the assignment. Certain functions, such as pharmacy or monitoring, may retain access to the code for accountability and safety.

Question 5Scientific Concepts and Research Design

A primary endpoint in a confirmatory trial should be:

  1. Pre-specified in the protocol and directly measure clinical benefit Correct answer.
  2. Changed at each interim analysis based on accumulating data
  3. A surrogate marker chosen mainly for convenience of measurement
  4. Selected after unblinding to reflect the largest observed difference

Explanation

The primary endpoint defines the main question of the trial and must be specified before data are unblinded to avoid bias. It should be clinically meaningful and reliably measurable in the study population.

Question 6Scientific Concepts and Research Design

Which element must be present in the informed consent process for trial participation to be ethically valid?

  1. A guarantee that the investigational product will be supplied free after the trial
  2. A statement that participation is voluntary and may be withdrawn at any time Correct answer.
  3. A commitment that adverse events will not be reported to the sponsor
  4. An assurance that the participant will receive the active treatment

Explanation

Valid consent requires that participation be voluntary and that participants understand they may withdraw at any time without penalty or loss of usual care. It also requires disclosure of risks, alternatives, and the possibility of receiving placebo.

Question 7Scientific Concepts and Research Design

What distinguishes a Phase III trial from a Phase II trial?

  1. Phase III trials are conducted only in healthy volunteers
  2. Phase III trials focus exclusively on dose selection
  3. Phase III trials assess risk-benefit in larger populations to support approval Correct answer.
  4. Phase III trials do not require a control group

Explanation

Phase III trials enroll larger, more representative populations to confirm efficacy and characterize safety for regulatory decision-making. Phase II trials are smaller and typically explore dose-response and preliminary activity.

Question 8Scientific Concepts and Research Design

In a superiority trial, the null hypothesis typically states that:

  1. The sample size is adequate to detect the target difference
  2. The new treatment is superior to the comparator by a pre-specified margin
  3. The new treatment is equivalent to the comparator within a margin
  4. There is no difference between the treatments being compared Correct answer.

Explanation

A superiority trial tests the null hypothesis of no difference against the alternative that a difference exists. Rejection of that null supports the claim that the new treatment is superior.

Question 9Scientific Concepts and Research Design

A participant randomized to Treatment A never takes any study drug and later experiences the primary outcome. Under the intention-to-treat principle, these data should be:

  1. Analyzed in the Treatment A group as randomized Correct answer.
  2. Analyzed in the comparator group according to actual treatment received
  3. Excluded from all analyses because of the protocol deviation
  4. Included only in the per-protocol analysis and excluded from the primary analysis

Explanation

Intention-to-treat analyzes participants according to the group to which they were randomized, regardless of adherence. This preserves the prognostic balance created by randomization and avoids bias from selective exclusion.

Question 10Scientific Concepts and Research Design

A two-sided test conducted at alpha = 0.05 controls the probability of:

  1. Incorrectly rejecting the null hypothesis when it is true Correct answer.
  2. Incorrectly concluding equivalence when the treatments truly differ
  3. Obtaining a sample mean exactly equal to the population mean
  4. Failing to detect a true treatment difference

Explanation

Alpha is the pre-specified probability of a type I error, meaning a false-positive rejection of a true null hypothesis. It is set by the investigator and is distinct from beta, which governs type II error.

Question 11Scientific Concepts and Research Design

A trial has 80% power to detect a specified difference at alpha 0.05. This means that:

  1. Eighty percent of enrolled participants will complete all study visits
  2. The observed treatment effect is expected to be within 80% of the true population effect
  3. There is an 80% probability that the null hypothesis is true
  4. If the target difference truly exists, 80% of such trials yield a significant result Correct answer.

Explanation

Power is the probability of rejecting the null hypothesis when the specified alternative is true. It depends on effect size, variability, alpha, and sample size, and says nothing about the probability that the null itself is true.

Question 12Scientific Concepts and Research Design

A trial reports a risk difference of 2.1% with a 95% confidence interval of -0.5% to 4.7%. How should this be interpreted?

  1. The treatment effect is exactly 2.1% in the population
  2. Effects from small harm to moderate benefit are compatible, and the result is not significant Correct answer.
  3. The treatment is statistically significantly better at the 0.05 level
  4. Ninety-five percent of participants benefited by between -0.5% and 4.7%

Explanation

Because the confidence interval includes zero, the result is not statistically significant at the two-sided 0.05 level. The interval describes the range of effects compatible with the data, spanning from a small harm to a moderate benefit.

Question 13Scientific Concepts and Research Design

In a non-inferiority trial comparing a new treatment with an active control, non-inferiority is concluded when:

  1. The confidence interval for the difference excludes the margin in the favorable direction Correct answer.
  2. The new treatment separates from placebo in a separate placebo-controlled trial
  3. The upper bound of the confidence interval falls below zero
  4. The point estimate numerically favors the new treatment over the active control

Explanation

Non-inferiority is judged against a pre-specified margin, and the entire confidence interval must lie on the favorable side of that margin. A point estimate that merely favors the new treatment is insufficient because it ignores statistical uncertainty.

Question 14Scientific Concepts and Research Design

Why might a sponsor use stratified randomization with blocks?

  1. To guarantee that no imbalance occurs in unmeasured confounders
  2. To balance key prognostic factors across arms and keep allocations roughly equal over time Correct answer.
  3. To allow investigators to predict the next assignment
  4. To remove the need for a random number generator

Explanation

Stratification balances important baseline factors within each stratum, while blocking prevents large drift in group sizes as enrollment proceeds. Only measured factors can be stratified; unmeasured confounding is addressed only probabilistically.

Question 15Scientific Concepts and Research Design

Why does a crossover trial usually require a washout period between treatment periods?

  1. To prevent carryover effects from the first period contaminating the second Correct answer.
  2. To allow participants to withdraw consent without penalty
  3. To reduce the total number of participants required
  4. To make the trial double-blind

Explanation

In a crossover design each participant receives more than one treatment, so residual effects of the earlier treatment could distort the comparison in later periods. A washout allows the effect to dissipate and the disease state to return toward baseline.

Question 16Scientific Concepts and Research Design

In an observational cohort, older participants are more likely to receive Drug X and are also more likely to die. In this setting, age functions as:

  1. A confounder Correct answer.
  2. A mediator
  3. An effect modifier
  4. An outcome measure

Explanation

A confounder is associated with both the exposure and the outcome and is not on the causal pathway between them, which is the case for age here. Failure to adjust for it would mix the effect of age with the effect of Drug X.

Question 17Scientific Concepts and Research Design

Recruiting participants for a hypertension trial exclusively from a specialist referral clinic most directly threatens:

  1. The internal validity of the randomization procedure
  2. The accuracy of the informed consent documentation
  3. The reliability of the electronic data capture system
  4. External validity, or the generalizability of the results Correct answer.

Explanation

A referral clinic population tends to be more severely affected and differently managed than the broader patient population. Results from such a sample may not generalize, even if the internal comparison remains valid.

Question 18Scientific Concepts and Research Design

Which change increases the sample size needed to detect a fixed treatment difference with 90% power?

  1. Increasing the expected effect size
  2. Raising the type I error rate from 0.01 to 0.05
  3. Reducing the anticipated dropout rate
  4. Increasing the variability of the outcome measure Correct answer.

Explanation

Greater variability inflates the standard error, so more participants are needed to resolve a given difference. Sample size falls when the effect size grows, alpha is relaxed, or fewer participants are lost to follow-up.

Question 19Scientific Concepts and Research Design

Blinding of outcome assessors matters most when the endpoint is:

  1. A laboratory value measured by a central automated analyzer
  2. A genetic marker determined by a fixed assay
  3. A clinician-rated symptom scale requiring subjective judgment Correct answer.
  4. All-cause mortality obtained from a national registry

Explanation

Subjective assessments are susceptible to conscious or unconscious bias when the assessor knows the treatment assignment. Objective, machine-derived, or registry-based measures are far less vulnerable to this form of bias.

Question 20Scientific Concepts and Research Design

A trial is positive overall, but a significant effect appears in only one of eight exploratory subgroups. The most appropriate interpretation is:

  1. The treatment should be approved only for that subgroup
  2. The overall result should be discarded in favor of the subgroup result
  3. The finding is hypothesis-generating and requires confirmation in a pre-specified analysis Correct answer.
  4. The finding proves the treatment is ineffective in all other subgroups

Explanation

Testing many subgroups without adjustment raises the likelihood of a chance finding, and the trial was not powered for subgroup comparisons. Such results should be labeled exploratory and confirmed in a pre-specified or prospectively designed analysis.

Question 21Scientific Concepts and Research Design

A trial evaluates its primary endpoint at three interim analyses and at the final analysis without any statistical adjustment. The main consequence is:

  1. The confidence intervals become narrower than planned
  2. The type I error rate rises above the nominal level Correct answer.
  3. The estimated treatment effect becomes unbiased
  4. The power rises above the planned level

Explanation

Each additional look at accumulating data creates another opportunity to cross a significance boundary, so repeated unadjusted testing inflates the false-positive rate. Alpha-spending functions or group-sequential boundaries are used to preserve the overall error rate.

Question 22Scientific Concepts and Research Design

Which approach best preserves the overall type I error when a trial permits early stopping for efficacy?

  1. Stopping enrollment once conditional power exceeds 50%
  2. Increasing the target sample size after the interim review
  3. Using an alpha-spending function that allocates error across the planned looks Correct answer.
  4. Applying a fixed alpha of 0.05 at each interim and final analysis

Explanation

An alpha-spending function assigns a portion of the total type I error to each planned analysis, so the cumulative false-positive risk stays at the nominal level. This permits early stopping while keeping the overall error rate controlled.

Question 23Scientific Concepts and Research Design

Which statement best describes a valid surrogate endpoint?

  1. It must be measured invasively in every participant
  2. It replaces the need for randomization in confirmatory trials
  3. It is any biomarker that changes measurably during treatment
  4. It is a marker with demonstrated ability to predict the clinical benefit of a treatment Correct answer.

Explanation

A surrogate is valid only when evidence shows that effects on the marker reliably predict effects on the clinical outcome of interest. Change alone is insufficient, since many markers respond to therapy without translating into patient benefit.

Question 24Scientific Concepts and Research Design

Multiple imputation using a missing-at-random assumption is most defensible when:

  1. The probability of missingness depends on the unobserved outcome value itself
  2. Missing values are replaced by the group mean of the observed values
  3. Missingness depends on observed variables included in the imputation model Correct answer.
  4. Complete cases are excluded from every analysis

Explanation

Missing at random allows the probability of missingness to depend on observed data that are included in the imputation model. If missingness depends on the unobserved value itself, the assumption is violated and sensitivity analyses under plausible departures are needed.

Question 25Scientific Concepts and Research Design

A meta-analysis reports an I-squared value of 75%. This indicates that:

  1. The pooled estimate has a 75% probability of being correct
  2. Seventy-five percent of the included studies were adequately randomized
  3. Most variability across study results reflects heterogeneity rather than chance Correct answer.
  4. Publication bias is present to a substantial degree

Explanation

I-squared estimates the proportion of total variability in effect estimates attributable to between-study heterogeneity rather than sampling error. A value of 75% signals substantial heterogeneity, prompting investigation of sources and consideration of a random-effects model.

Question 26Ethical and Participant Safety Considerations

A study team plans to minimize risks and maximize potential benefits for participants. Which Belmont Report principle does this most directly reflect?

  1. Respect for persons
  2. Justice
  3. Beneficence Correct answer.
  4. Integrity

Explanation

Beneficence requires researchers to maximize possible benefits and minimize possible harms. Respect for persons focuses on autonomy and informed consent, while justice concerns fair distribution of research burdens and benefits. Integrity is not one of the three Belmont principles.

Question 27Ethical and Participant Safety Considerations

Which element is generally required for documented informed consent under ICH-GCP and U.S. regulations?

  1. Participant's signature and date Correct answer.
  2. IRB chair's signature and date
  3. Witness signature for every participant
  4. Sponsor's signature and date

Explanation

Documented consent generally requires the participant or legally authorized representative to sign and personally date the consent form. A witness is required only in specific circumstances, such as when the participant cannot read. Sponsor and IRB chair signatures are not part of the participant's consent document.

Question 28Ethical and Participant Safety Considerations

What is the primary role of a Data Safety Monitoring Board in a clinical trial?

  1. To obtain informed consent from participants
  2. To monitor participant safety and recommend study changes Correct answer.
  3. To approve protocol amendments before IRB review
  4. To verify source documents against case report forms

Explanation

A Data Safety Monitoring Board reviews accumulating safety and efficacy data and recommends whether a trial should continue, be modified, or be stopped. It does not obtain consent, approve amendments in place of the IRB, or perform routine source document verification.

Question 29Ethical and Participant Safety Considerations

An investigator has a significant financial interest in the sponsor company. What is the most appropriate action?

  1. Transfer it to a family member
  2. Continue without disclosure if the amount is small
  3. Keep it confidential to avoid bias concerns
  4. Disclose it to the IRB and institution per policy Correct answer.

Explanation

Significant financial interests that could affect the research must be disclosed to the IRB and institution according to conflict-of-interest policies. Disclosure allows appropriate management, such as recusal or additional oversight. Confidentiality or transfer to a family member does not eliminate the conflict.

Question 30Ethical and Participant Safety Considerations

In research involving children, which statement best describes assent?

  1. A document signed only by the IRB
  2. A waiver of all informed consent requirements
  3. A child's affirmative agreement, obtained with parental permission Correct answer.
  4. A legally binding contract that replaces parental permission

Explanation

Assent is a child's affirmative agreement to participate, obtained in addition to permission from a parent or legally authorized representative. It is not a legally binding contract and does not replace parental permission. IRB approval and consent requirements still apply.

Question 31Ethical and Participant Safety Considerations

Under ICH-GCP, how long should essential trial documents generally be retained after the trial is completed?

  1. At least 2 years after formal discontinuation, or longer Correct answer.
  2. For exactly 10 years in all countries
  3. Until the end of the calendar year
  4. Only until the database is locked

Explanation

ICH-GCP generally requires essential documents to be retained for at least 2 years after formal discontinuation of the trial, or longer if required by applicable regulations. Local laws may impose longer retention periods. Retention does not end when the database is locked.

Question 32Ethical and Participant Safety Considerations

Which event meets the definition of a serious adverse event?

  1. An event causing hospitalization or prolonged hospitalization Correct answer.
  2. A mild headache that resolves with acetaminophen
  3. An event reported after the final visit
  4. Any laboratory abnormality without symptoms

Explanation

A serious adverse event is one that results in death, is life-threatening, requires or prolongs hospitalization, causes persistent disability, is a congenital anomaly, or requires intervention to prevent a serious outcome. Symptom severity alone does not define seriousness. Timing after the final visit also does not determine seriousness.

Question 33Ethical and Participant Safety Considerations

Under U.S. regulations, how often must an IRB conduct continuing review of a research study that is not eligible for exemption?

  1. At least once per year Correct answer.
  2. Every 3 years
  3. Only when the sponsor requests it
  4. Every 6 months for all studies

Explanation

U.S. regulations require continuing review at intervals appropriate to the degree of risk, but not less than once per year for studies that require continuing review. The IRB may set a shorter interval for higher-risk research. Sponsor request is not the governing standard.

Question 34Ethical and Participant Safety Considerations

An investigator wants to place a newspaper advertisement to recruit participants. What should happen before the advertisement is used?

  1. The IRB should review and approve it Correct answer.
  2. The investigator may use it after enrollment begins
  3. The advertisement must contain the word free
  4. The sponsor must submit it to FDA for approval

Explanation

Recruitment advertisements are part of the informed consent and recruitment process and generally require IRB review and approval before use. The IRB assesses whether the advertisement is accurate and not unduly coercive. FDA approval of each advertisement is not required, and use before approval is inappropriate.

Question 35Ethical and Participant Safety Considerations

A potential participant has advanced dementia and cannot provide informed consent. What is the most appropriate approach under U.S. regulations?

  1. Obtain consent from any adult who accompanies the person
  2. Rely on the person's verbal agreement only
  3. Enroll the person without consent because of dementia
  4. Obtain consent from a legally authorized representative Correct answer.

Explanation

For adults who lack decision-making capacity, consent is generally obtained from a legally authorized representative in accordance with applicable law and IRB requirements. Any available assent from the participant should also be sought when appropriate. A casual companion or verbal agreement alone is not sufficient.

Question 36Ethical and Participant Safety Considerations

Research involving prisoners requires additional safeguards primarily because prisoners:

  1. May face coercion due to incarceration Correct answer.
  2. Cannot understand any research information
  3. Are always terminally ill
  4. Are excluded from all federal research

Explanation

Prisoners are considered a vulnerable population because incarceration may limit voluntariness and create undue influence. Additional safeguards help ensure that participation is truly voluntary and that risks are justified. Prisoners are not categorically excluded from all research, nor are they presumed unable to understand information.

Question 37Ethical and Participant Safety Considerations

A study will use identifiable protected health information from a covered entity. What document is generally required in addition to informed consent?

  1. Sponsor confidentiality agreement only
  2. Certificate of destruction
  3. HIPAA authorization, unless waived Correct answer.
  4. FDA Form 483

Explanation

Use or disclosure of identifiable protected health information by a covered entity generally requires a valid HIPAA authorization, unless the IRB or privacy board approves a waiver. Informed consent alone does not satisfy HIPAA requirements. A sponsor confidentiality agreement does not replace participant authorization.

Question 38Ethical and Participant Safety Considerations

A participant experiences an unanticipated problem involving risk to others. What should the investigator do?

  1. Report it only to the participant's family
  2. Wait until the final report to inform the IRB
  3. Discard it because no harm occurred
  4. Report it promptly to the IRB and sponsor Correct answer.

Explanation

Unanticipated problems involving risks to participants or others must be reported promptly to the IRB and sponsor according to regulatory and institutional timelines. Waiting until the final report can delay necessary protective action. Lack of actual harm does not eliminate the reporting obligation.

Question 39Ethical and Participant Safety Considerations

Under ICH-GCP, an investigator should report a serious adverse event to the sponsor:

  1. Immediately, with follow-up as available Correct answer.
  2. Within 30 days regardless of urgency
  3. Only in the final study report
  4. After the participant is discharged

Explanation

ICH-GCP requires the investigator to report serious adverse events to the sponsor immediately, except those the protocol identifies as not requiring immediate reporting. Follow-up information should be provided as it becomes available. Waiting for discharge or the final report can delay safety review.

Question 40Ethical and Participant Safety Considerations

A participant missed a scheduled study visit because of a personal conflict. This is best classified as:

  1. An unanticipated problem in all cases
  2. A protocol violation requiring termination
  3. A serious adverse event
  4. A protocol deviation Correct answer.

Explanation

A missed visit is a departure from the protocol and is generally classified as a protocol deviation. It does not by itself meet the definition of a serious adverse event or require study termination. Not every deviation is an unanticipated problem.

Question 41Ethical and Participant Safety Considerations

Which approach best minimizes undue influence when paying participants?

  1. Pay only participants with favorable outcomes
  2. Withhold payment information until enrollment
  3. Pay a large completion bonus to ensure retention
  4. Pro-rate payment and disclose it in consent Correct answer.

Explanation

Payment should be disclosed in the consent form and should not be so large that it unduly influences participation. Pro-rating payment for time and effort can reduce coercion and is generally acceptable. Withholding payment information or paying only for favorable outcomes is unethical.

Question 42Ethical and Participant Safety Considerations

Before a study coordinator performs a delegated study task, the investigator should ensure that the coordinator:

  1. Has been trained and delegation is documented Correct answer.
  2. Has paid the IRB review fee
  3. Has no contact with participants
  4. Is listed as a co-author on publications

Explanation

The investigator remains responsible for study conduct and must ensure that delegated staff are qualified and trained for their assigned tasks. Delegation should be documented, for example in a delegation log. Paying IRB fees or authorship is unrelated to task qualification.

Question 43Ethical and Participant Safety Considerations

A participant decides to withdraw from a clinical trial. Which statement is most consistent with ethical requirements?

  1. The participant must complete all scheduled visits
  2. Future data must always be deleted automatically
  3. The investigator may remove the consent form from the file
  4. The participant may withdraw at any time without penalty Correct answer.

Explanation

Participants may withdraw from research at any time without penalty or loss of benefits to which they are otherwise entitled. The investigator should explain the consequences of withdrawal and options for use of data already collected. Consent forms remain part of the study records.

Question 44Ethical and Participant Safety Considerations

Which selection practice best reflects the Belmont principle of justice?

  1. Fair distribution of research burdens and benefits Correct answer.
  2. Excluding all vulnerable persons from every study
  3. Selecting participants for investigator convenience
  4. Enrolling only people who can easily attend visits

Explanation

Justice requires fair and equitable selection of participants and distribution of research burdens and benefits. Convenience-based recruitment and automatic exclusion can unjustly concentrate research burdens on particular groups. Vulnerable populations should be included when appropriate with additional safeguards.

Question 45Ethical and Participant Safety Considerations

An IRB may approve a waiver of informed consent for minimal-risk research only if the waiver meets certain criteria. Which criterion is required?

  1. The sponsor agrees to pay all participants
  2. All participants are adults
  3. The research includes a placebo control
  4. It will not adversely affect rights and welfare Correct answer.

Explanation

Waiver criteria include that the research involves no more than minimal risk, the waiver will not adversely affect participants' rights and welfare, the research could not practicably be carried out without the waiver, and appropriate information is provided afterward when feasible. Placebo use, sponsor payment, and adult status are not waiver criteria.

Question 46Ethical and Participant Safety Considerations

Under U.S. regulations, exception from informed consent for emergency research requires, among other things:

  1. Prior consent from every family member
  2. Community consultation and public disclosure Correct answer.
  3. Enrollment limited to children
  4. An FDA waiver for every study

Explanation

Emergency research conducted under the exception from informed consent requires community consultation and public disclosure, among other safeguards. Consent from every family member in advance is not feasible in emergency settings and is not the requirement. Children are not the intended population for this exception.

Question 47Ethical and Participant Safety Considerations

For research involving pregnant women, which condition is generally required for approval?

  1. Fetal risks are minimized and consent addresses them Correct answer.
  2. The research has no prospect of benefit and no risk
  3. No additional review is needed
  4. Only the father's consent is required

Explanation

Research involving pregnant women generally requires that risks to the fetus be minimized and that informed consent address risks to the woman and fetus. The research may offer direct benefit or be otherwise permissible under the regulations. Additional IRB review and safeguards apply.

Question 48Ethical and Participant Safety Considerations

During a study MRI, a participant's scan reveals a possible brain tumor unrelated to the research. What is the most appropriate action?

  1. Post it on the study website
  2. Follow the protocol plan and refer as appropriate Correct answer.
  3. Bill the participant before disclosing
  4. Ignore it because it is outside the endpoint

Explanation

Incidental findings should be managed according to the protocol and consent documents, which should describe whether and how findings will be communicated. Appropriate clinical referral is generally needed when a finding may affect the participant's health. Ignoring the finding or delaying disclosure for billing is unethical.

Question 49Ethical and Participant Safety Considerations

A participant develops a serious medical condition, and knowledge of treatment assignment could affect urgent care. What is the most appropriate action?

  1. Unblind all participants in the trial
  2. Ask the participant to guess their treatment
  3. Keep the blind because randomization is absolute
  4. Use the prespecified emergency unblinding process Correct answer.

Explanation

Emergency unblinding should follow the protocol's prespecified process and be limited to what is necessary for the participant's care. The blind is not absolute when knowledge of assignment is needed for safe management. Unblinding all participants would compromise the trial unnecessarily.

Question 50Ethical and Participant Safety Considerations

Which statement best reflects the ethical principles of the Declaration of Helsinki?

  1. Participant well-being takes precedence over science and society Correct answer.
  2. Placebo controls are always preferred to active controls
  3. Ethics review is optional for observational research
  4. Research may proceed if it benefits society, regardless of consent

Explanation

The Declaration of Helsinki emphasizes that the well-being of the individual research participant takes precedence over the interests of science and society. Informed consent and ethics review remain fundamental safeguards. Placebo use and review requirements depend on the specific context and regulations.